Hire an Advanced Robo-Advisor to Trade ALXN on Your Behalf.

Stock Detail Header
  • Street Sentiment
  • Personalized Strategy
  • Free Trading Simulator
Get Started
Stock Details
  • PRICE$113.64
  • PRICE CHANGE$0.04
  • % CHANGE0.04%
  • TWEETS20
  • CONSENSUSBUY

Trends

Course of Action

BUY

Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell

DAILY PRICE CHANGE VS SENTIMENT

  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

What is Robo investing?

Smart Auto-Trading is an advanced robo-advisor designed to provides investors with a a state of the art automated trading tool to trade the S&P 500. Its robo is designed to screens, monitors and auto-trades elite stocks like ALEXION PHARMACEUTICALS, INC. (ALXN) using artificial intelligence, social media and market data to augments your potential as an investor.

What is it good at?

If you are interested in systematic, active investing, Smart Auto-Trading can be a great alternative to passive investing funds. Smart Auto-Trading uses artificial intelligence concepts to screen, monitor and auto-trade stocks. Used in a tax-deferred account such as an IRA, SIMPLE IRA, Rollover IRA, Keogh, 529 College Plan or UGMA it auto-trades systematically using your carefully defined strategy. Using Smart Auto-Trading is like having a professional trader working for you. You turn it on and it just works.

Smart Auto-Trading actively trades the S&P 500 day-in and day-out in your account while you attend more important life events. Because of the systematic nature of Smart Auto-Trading, your account has the potential to grow at a higher rate than if you were to use a passive investment vehicle such as an index fund or a mutual fund. Systematic active trading using artificial intelligence holds the potential to grow the account faster.

Using Smart Auto-Trading is Easy

To connect Smart Auto-Trading to your account you will need to open an account with Ally Invest, one of the most trusted broker/dealer in the United States. Ally Invest is the brokerage firm Stock Circles uses to auto-trade because Ally Invest offers a very competitive price per trade.

To open an account, please go to Ally Invest's account opening page is available at: https://invest.ally.com/ola/

Once the account is open, you are ready to transfer your money into the newly opened account. To do so, you will need to send a copy of your 401K or other account statement to Ally Invest as well as transfer instructions to support@invest.ally.com. Once they receive your instructions, a Customer Support specialist will help you complete the transfer.

After a few business days, the account will be funded and you will be ready to auto-trade using Smart Auto-Trading.

While this is in progress, you might want to test your strategy in simulation mode free of charge at stockcircles.com. Doing so will help you get comfortable with the product's benefits.

Benefits

There are clear benefits associated with using a robo-advisor such as Smart Auto-Trading to help you reach your financial goals. Smart Auto-Trading simplifies stock investing down to a few steps. It auto-trades for you, using your personalized strategy, while you attend more important life events.

Using Smart Auto-Trading is like having thousands of traders working for you to help you reach your financial goals.

Smart Auto-Trading actively trades which is different from passive investing. The robo is on the lookout working to maximize your potential every business day of the year. It trades on the news taking advantage of price changes and trends by listening into trader's communications and by validating this information with market data.

Smart Auto-Trading is one of the first robo-advisor to take advantage of Government grade listening technology, artificial intelligence, social media and market data natively.

Try Smart Auto-Trading today!

You can test Smart Auto-Trading in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. Therefore, you should assume that the future performance of any specific investment, investment strategy (including robo-strategies), or product made in reference directly or indirectly on this website, will be profitable or equal to corresponding indicated performance levels. Robot-Advisors like other investment methods rely on favorable market conditions to provide positive outcomes.

ALEXION PHARMACEUTICALS, INC. (ALXN) News

Why This Biotech Could See 30% Upside In The Second Quarter

Alexion Pharmaceuticals (ALXN) could see as much as 30% upside if its rare blood disease drug outperforms its already approved medication, Soliris, in a pair of Phase 3 trials, an analyst said Friday, prodding the company's stock to pop.

In early trading on the stock market today, Alexion surged 7.2% to close at 114.46. The analysis came a day after Alexion announced a partnership that will allow it to use Halozyme Therapeutics' (HALO) technology for drug injections.

The biotech is testing a drug dubbed ALXN1210 in blood diseases known as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Results are expected in the second quarter of 2018.

"We see as much as 30% upside from the current stock price to our base case outcome from the trials," Leerink analyst Geoffrey Porges said in a note to clients.

Soliris is already approved to treat both conditions. But the drug is set to lose patent protection in 2027 and 2023 in the U.S. and Europe, respectively. Alexion is betting on Soliris patients switching to ALXN1210 if it's approved.

Adoption of ALXN1210 will be higher if it proves superior to Soliris in clinical trials, rather than simply non-inferior or inferior, Porges said. He sees 30% and 20% upside if ALXN1210 proves superior or non-inferior to Soliris, and 5%-10% downside if it fails.

"We model that Alexion can convert 80% of patients within three years if ALXN1210 shows superiority, but only 50% if the outcome is only non-inferiority," he said. If ALXN1210 proves inferior to Soliris, it will likely be discontinued.

Porges suggests Alexion could become a takeout candidate if ALXN1210 fails, causing volatility in the stock. Even without ALXN1210, its cash flows from 2018-27 support a 90-100 stock price.

"We believe the remaining assets would still have a high likelihood of being purchased at our downside valuation and management is likely to be a willing seller in that low probability scenario," he said.

Get Started today! - Risk Free

Investors who like ALEXION PHARMACEUTICALS, INC. (ALXN) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles